<DOC>
	<DOCNO>NCT00645034</DOCNO>
	<brief_summary>To investigate effect single dose sildenafil ( 100 mg ) placebo blood pressure pulse rate subject take doxazosin benign prostatic hyperplasia ( BPH ) . To investigate pharmacokinetics doxazosin co-administered sildenafil 100 mg , investigate safety toleration sildenafil 100 mg co-administered doxazosin .</brief_summary>
	<brief_title>A Study Investigate Effects Blood Pressure Pulse Rate Single 100mg Dose Sildenafil Patients With Benign Prostatic Hyperplasia Who Are Being Treated With Doxazosin</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Doxazosin</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>patient weigh 132 220 lb ( 60 100 kg ) benign prostatic hyperplasia ( BPH ) total PSA ( prostate specific antigen ) measurement less equal 10 Âµg/L within 12 month prior screen , currently doxazosin treatment BPH , treat doxazosin minimum 2 month prior first dose study medication , receive minimum 4 mg doxazosin daily ( doxazosin supply study ) 2 week prior first dose study medication . subject recent history ( i.e . within 6 month prior screen ) stroke myocardial infarction subject severe cardiovascular disorder unstable angina severe congestive heart failure subject know hereditary degenerative retinal disorder , retinitis pigmentosa subject supine systolic/diastolic blood pressure &gt; 170/100 mmHg &lt; 100/60 mmHg either screen predose measurement subject receive antihypertensive therapy doxazosin 3 week prior first dose study medication .</criteria>
	<gender>Male</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>